Covid-19: Molnupiravir does not cut hospital admissions or deaths in vaccinated people at high risk, trial finds - ISS-G20 Laboratorium Repository

The antiviral drug molnupiravir does not reduce hospital admissions or deaths among vaccinated high risk patients with covid-19 infection, show the results of a landmark trial that included more than 25 000 participants.

However, the oral treatment was associated with reduced viral detection and load, and patients recovered around four days more quickly than those who received usual care. The Panoramic study, now peer reviewed and published in the Lancet, was first available as a preprint in October.

Entire content available on: https://www.bmj.com/content/379/bmj.o3055